Investors Iron Out AMAG Ferumoxytol Doubts
This article was originally published in The Pink Sheet Daily
Executive Summary
Shades of MGI’s Aloxi: CMS rule could pay off.
You may also be interested in...
FDA Panel Votes Against First-line Use For Luitpold’s Iron Deficiency Drug Injectafer
Concerned about off-label use of the drug in patients with critical kidney disease, advisory committee suggests that if approved, Injectafer label should include “very descriptive prescribing” instructions.
AMAG Seeks Dialysis And Pre-Dialysis CKD Indication For Ferumoxytol
A potential competitor, Luitpold’s Injectafer, is scheduled to go before an FDA advisory committee Feb. 1.
Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition
MGI sale comes less than two weeks after the biopharma said it was exploring "strategic alternatives."